Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
Clinical trial NCT06552572 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06552572
- Sponsor
- Samsung Medical Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-26
- Primary completion
- 2026-06-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.